Xilio Therapeutics, Inc. (XLO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98422T2096
Xilio Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 43.77 m USD |
| Operating income | -41.98 m USD |
| EBIT | -35.04 m USD |
| Net income | -35.04 m USD |
| Diluted EPS – continuing operations | -4.19 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
More stocks
- Aquawalk Group Berhad (0380.KL)
- Frontier Lithium Inc (FL.V)
- Hotron Precision Electronic Industrial Co Ltd (3092.TW)
- Topview Optronics Corporation (6556.TWO)
- Tifa Finance Tbk (TIFA.JK)
- Anfield Resources Inc (AEC.V)
- Sahamit Machinery Public Company Limited (SMIT.BK)
- Concorde International Group Ltd Class A Ordinary Shares (CIGL)
- IB Acquisition Corp. (IBAC)
- Chien Shing Stainless Steel Co Ltd (2025.TW)
- Renova Energia S.A (RNEW3.SA)
- Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.